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Abstract: Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and
hepatocellular carcinoma (HCC) which are leading indications of liver transplantation (LT). To date,
there is no vaccine to prevent HCV infection and LT is invariably followed by infection of the
liver graft. Within the past years, direct-acting antivirals (DAAs) have had a major impact on
the management of chronic hepatitis C, which has become a curable disease in the majority of
DAA-treated patients. In contrast to DAAs that target viral proteins, host-targeting agents (HTAs)
interfere with cellular factors involved in the viral life cycle. By acting through a complementary
mechanism of action and by exhibiting a generally higher barrier to resistance, HTAs offer a
prospective option to prevent and treat viral resistance. Indeed, given their complementary
mechanism of action, HTAs and DAAs can act in a synergistic manner to reduce viral loads. This
review summarizes the different classes of HTAs against HCV infection that are in preclinical or
clinical development and highlights their potential to prevent HCV infection, e.g., following LT, and
to tailor combination treatments to cure chronic HCV infection.
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1. Introduction
Hepatitis C virus (HCV) is a hepatotropic enveloped RNA virus of the Flaviviridae family.
It is a highly variable virus that has been classified into six major genotypes [1]. Approximately
170 million individuals worldwide are infected by HCV. Chronically HCV-infected individuals are
at risk for developing cirrhosis and hepatocellular carcinoma (HCC) which are major indications
for liver transplantation (LT). There is no vaccine to prevent HCV infection and, until recently,
antiviral therapy (based on pegylated (PEG) interferon (IFN) alpha and ribavirin) only enabled a
cure for less than half of the patients, with strong differences in treatment outcome depending on
the genotype. Within the past years, with the sequential approval of novel antivirals specifically
targeting viral proteins (direct-acting antivirals (DAAs)), chronic hepatitis C has become a curable
disease in the majority of treated patients and the most recent DAAs act in a pan-genotypic manner
(reviewed in [2]). Several novel antivirals are in late-stage clinical development and will further
broaden the therapeutic arsenal against HCV and enable the tailoring of combination treatments for
distinct patient groups.
Antivirals can be classified into two distinct categories depending on whether they target viral
proteins, i.e., DAAs, or interfere with cellular factors involved in viral infection, i.e., host-targeting
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agents (HTAs). For many years, HCV-host interactions have remained largely elusive due to the
lack of robust model systems, and anti-HCV drug development has paralleled discoveries about the
molecular mechanisms of viral replication. Indeed, the establishment of increasingly sophisticated
model systems to study HCV infection (reviewed in [3–5]) has enabled researchers to characterize the
molecular mechanisms underlying the HCV life cycle in great detail (reviewed in [6–9]) and to design
a wide variety of antivirals targeting various steps of the viral replication cycle (reviewed in [8,10]).
While several HTAs had been developed to characterize the HCV replication cycle and corroborate
the importance of defined host factors for distinct steps of viral infection, others have been uncovered
through functional screening approaches aimed at repurposing existing small molecules/approved
drugs [11–13]. This review summarizes the different classes of HTAs against HCV infection and
highlights their potential for antiviral therapy to prevent viral resistance.
2. HTAs to Inhibit Various Steps of the HCV Life Cycle
The HCV life cycle can be subdivided into five different steps, including viral entry, viral
translation, viral replication, viral assembly, and release of new virions. Each of these steps requires
defined virus-host interactions to ultimately enable the virus to establish chronic infection. Given the
amount of host factors involved in the HCV life cycle, this review solely focuses on some of these host
factors that have been suggested to represent potential targets for HTAs during distinct steps of the
HCV life cycle within hepatocytes (Figure 1). Other compounds exhibiting a broader mechanism
of action by modulating the host’s immune responses, also termed biological response modifiers






model  systems  to  study  HCV  infection  (reviewed  in   [3,  4,  5])  has  enabled  researchers  to 
characterize  the molecular mechanisms  underlying  the HCV  life  cycle  in  great  detail  (reviewed 
in   [6,  7,  8,  9])  and  to  design  a  wide  variety  of  antivirals  targeting  various  steps  of  the  viral 
replication cycle (reviewed in  [8, 10]). While several HTAs had been developed to characterize the 
HCV replication cycle and corroborate the  importance of defined host  factors for distinct steps of 
viral  infection,  others  have  been  uncovered  through  functional  screening  approaches  aimed  at 




The HCV  life  cycle  can  be  subdivided  into  five  different  steps,  including  viral  entry,  viral 
translation, viral replication, viral assembly, and release of new virions. Each of these steps requires 
defined virus‐host  interactions  to ultimately enable  the virus  to establish chronic  infection. Given 
the amount of host  factors  involved  in  the HCV  life  cycle,  this  review  solely  focuses on  some of 
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therapy. HCV  interacts with the basolateral membrane of hepatocytes, resulting  in viral entry  into 
the host cell. The virus is internalized via endocytosis and translation of the HCV RNA occurs in the 
cytoplasm following viral fusion and uncoating. Viral replication takes place within the cytoplasm 
in  perinuclear  endoplasmic  reticulum  (ER)‐derived  membranes  called  the  “membranous  web”. 
Progeny virions are assembled on cytosolic  lipid droplets and subsequently  transported along  the 
secretory pathway and maturated  in the Golgi before their release through microtubular transport 
and endocytic recycling compartment. Targets for antiviral therapy are highlighted in red. 
Figure 1. Schematic representation of the hepatitis C virus (HCV) life cycle and targets for antiviral
therapy. HCV interacts with the basolateral membrane of hepatocytes, resulting in viral entry into
the host cell. The virus is internalized via endocytosis and translation of the HCV RNA occurs in the
cytoplasm following viral fusion and uncoating. Viral replication takes place within the cytoplasm
in perinuclear e doplasmic reticulum (ER)-derived membranes called the “membranous web”.
Progeny virions are assembled on cytosolic lipid droplets and ubsequently transpo ted along the
secretory pathway and maturated in he Golgi before their release t rough microtubular transport
and endocytic recycling compartment. Targets for antiviral therapy are highlighted in red.
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Table 1. Stage of development of host-targeting agents (HTAs) for prevention and/or treatment of
HCV infection. Only HTAs having at least reached in vivo preclinical development are listed.
Category Target Compounds Stage of Development References
Entry
inhibitors
CD81 mAbs Mouse model [18]
SR-BI
mAbs Mouse model [19–21]
ITX-5061 Phase 1 [22,23]
CLDN1 mAbs Mouse model [24]
EGFR Erlotinib Phase 1/2 NCT01835938
NPC1L1 Ezetimide Mouse model [25]
Endocytosis/fusion
Silymarin/silibinin Phase 2/3 [26,27]
Chloroquine Phase 4 NCT02058173
Translation
inhibitors miR-122 Miravirsen Phase 2 [28,29]
Replication
inhibitors
miR-122 Miravirsen Phase 2 [28,29]
HMGCoA reductase Statins Phase 3 [30,31]
Cyclophilin
Alisporivir Phase 2/3 [32]
SCY-635 Phase 2 [33]
NIM811 Phase 2 [34]
Assembly
inhibitors
α-glucosidase 1 Celgosivir Phase 2 [35]
DGAT-1 LCQ908 Phase 2 NCT01387958
Cyclophilin NIM811 Phase 2 [34]
PPARα Naringenin Phase 1 [36]





IFN-λ Phase 3 NCT01795911
TLR7 agonist Phase 1 [15,16]
TLR9 agonist Phase 3 [17]
Thymosin α1 Phase 3 [38]
Nitazoxanide Phase 2 [39,40]
mAbs: monoclonal antibodies, EGFR: epidermal growth factor receptor; IFN : interferon; TLR : Toll-like receptor;
CLDN1: claudin 1; CD81 : cluster of differentiation 81; SR-BI: scavenger receptor class B type I; NPC1L1:
Niemann-Pick C1-Like 1; HMGCoA: 3-hydroxy-3-methylglutaryl-coenzyme A; DGAT-1: diacylglycerol
O-acyltransferase 1; PPARα : peroxisome proliferator-activated receptor alpha; HNF4α : hepatocyte nuclear
factor 4 alpha. FDA: Food and Drug Administration; miR-122: microRNA-122
2.1. Entry Inhibitors to Prevent Initiation of Viral Infection and Viral Dissemination
The HCV entry process has been particularly well characterized within the past years
(for a review see [6]). The initial viral attachment on the hepatocyte cell surface is believed to
involve the interaction of the viral particle with heparan sulfate proteoglycans (HSPGs) [41–46],
particularly with syndecan 1 (SDC1) [47] and syndecan 4 (SDC4) [48], low density lipoprotein
receptor (LDLR) [49–53], and scavenger receptor class B type I (SR-BI) [54–59]. Interestingly, both
viral (HCV envelope glycoproteins) and host-derived (apolipoproteins) factors within the viral
particle appear to mediate this process (reviewed in [6,60]). Thus, the very first steps of viral
interaction with the host cell surface can be inhibited by targeting host factors expressed either on
the viral particle or on the host cell membrane (Figure 2). Indeed, it has been shown that synthetic
anti-lipopolysaccharide peptides that bind to heparan sulfate moieties on the cell surface as well as
antibodies directed against SR-BI or LDLR inhibit HCV attachment/infection [53,59,61]. Likewise,
peptides that mimic the receptor binding domain and the HSPG binding domain of apolipoprotein
E (apoE) inhibit HCV infection [45,48] and antibodies directed against apoE [45,62,63] as well as
preincubation of recombinant cell culture-derived HCV (HCVcc) with soluble LDLR have also been
shown to neutralize HCV infection, likely at the attachment/entry level [53,64]. Recently, it has been
suggested that low-molecular-weight lignin, a component of Lentinula edodes mycelia solid culture
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extract, that has been reported to exhibit hepatoprotective activity, might inhibit HCV attachment
through binding to apoE on the viral particle [65] given the structural similarity between lignin
sulfate and heparan sulfate [66]. Interestingly, lipoprotein lipase (LPL) increases HCV attachment
to the target cell by bridging virus-associated lipoproteins and cell surface heparan sulfate, whereas
antibodies as well as a small molecule inhibitor-targeting LDLR have been shown to decrease HCV
uptake [67,68]. In addition to its bridging function, LPL has been shown to inhibit viral entry
by immobilizing the virus at the cell surface [64,69]. Most recently, it has been shown that very
low-density lipoprotein (VLDL) is a serum component that inhibits HCV attachment [70].
Journal 2015, 7, page–page 
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Figure  2.  Schematic  representation  of HCV  entry. The  initial  viral  attachment  on  the  basolateral 
membrane  of  hepatocytes  is  believed  to  involve  the  interaction  of  the  viral  particle—both  
viral  (HCV  envelope  glycoproteins)  and  host‐derived  (apolipoproteins)  factors—with  
HSPGs  (heparan  sulfate  proteoglycans),  LDLR  (low  density  lipoprotein  receptor)  and  SR‐BI 
(scavenger  receptor  class  B  type  I).  Following  interaction  between  the  virus  and  different  host 
factors  expressed  at  the  hepatocyte  cell  surface,  including  CD81  (cluster  of  differentiation  81)  
and CLDN1  (claudin 1), as well  as  rearrangement of  cell  surface proteins,  the virus  is ultimately 
internalized  into  its host cell via clathrin‐mediated endocytosis. Additional host  factors,  including 
EGFR  (epidermal  growth  factor  receptor),  NPC1L1  (Niemann‐Pick  C1‐like  1)  and  TfR1  
(transferrin  receptor  1),  contribute  to  the  HCV  entry  process,  for  example  by  modulating 
intracellular  signaling  pathways  or  endocytosis.  Following  acidification  of  the  endosome  and 
subsequent  fusion  of  viral  and  endosomal  membranes,  the  viral  genome  is  released  into  the 
cytoplasm.  In addition  to  cell‐free virus entry, HCV has also been described  to  transmit between 
hepatocytes  through  direct  cell‐to‐cell  transmission  involving  CD81,  SR‐BI,  CLDN1,  OCLN 
(occludin), EGFR, EphA2 (ephrin receptor A2) and NPC1L1. HTAs can interfere with different steps 
of the HCV entry process as highlighted in red. 
Following  initial  attachment  to  the  hepatocyte  basolateral  membrane,  the  virus  interacts  
with additional host factors expressed at the hepatocyte cell surface to ultimately enter its host cell 
via  clathrin‐mediated  endocytosis.  It  is  believed  that  the  interaction  of  the  HCV  envelope 
glycoproteins E1  and E2 with SR‐BI, CD81, CLDN1 and potentially OCLN plays  a major  role  in  
this  process  and  some  of  these  host  factors  have  thus  been  suggested  to  play  the  role  of  
Figure 2. Schematic representation of HCV entry. The initial viral attachment on the basolateral
membrane of hepatocytes is believed to involve the interact on f the viral particle—both
viral (HCV envelope glycoproteins) and host-derived (apolipoproteins) factors—with HSPGs
(heparan sulfate proteoglycans), LDLR (low density lipoprotein receptor) and SR-BI (scavenger
receptor class B type I). Following interaction between the virus and different host factors expressed
at the hepatocyte c ll surface, inc uding CD81 (clust r f different ation 81) nd CLDN1 (claudin 1),
as well as rearrangement of cell surface proteins, the virus is ultimately internalized into its host
cell via clathrin-mediated endocytosis. Additional host factors, including EGFR (epidermal growth
factor receptor), NPC1L1 (Nieman -Pick C1-like 1) a d TfR1 (transferrin r ceptor 1), contribute to
the HCV entry process, for example by modulating intracellular signaling pathways or endocytosis.
Following acidification of the endosome and subsequent fusion of viral and endosomal membranes,
the viral genome is released into the cytoplasm. In addition to cell-free virus entry, HCV has also
been described to transmit between hepatocytes through direct cell-to-cell transmission involving
CD81, SR-BI, CLDN1, OCLN (occludin), EGFR, EphA2 (ephrin receptor A2) and NPC1L1. HTAs can
interfere with different steps of the HCV entry process as highlighted in red.
Following initial ttach ent to the hepat cyte basolat ral membrane, the virus interacts with
additional host factors expressed at the hepatocyte cell surface to ultimately enter its host cell via
clathrin-mediated endocytosis. It is believed that the interaction of the HCV envelope glycoproteins
E1 and E2 with SR-BI, CD81, CLDN1 and potentially OCLN plays a major role in this process and
some of these host factors have thus been suggested to play the role of “HCV receptors” [54,71–75].
Cluster of differentiation 63 (CD63) may also directly interact with HCV E2 and contribute to
HCV entry [76]. Of note, additional host factors, termed “co-factors”, including various kinases,
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e.g., epidermal growth factor receptor (EGFR), ephrin receptor A2 (EphA2), AP-2-associated protein
kinase 1 and cyclin G-associated kinase (GAK), as well as Niemann-Pick C1-like 1 (NPC1L1) and
transferrin receptor 1 (TfR1), also contribute to the HCV entry process, for example by modulating
intracellular signaling pathways or endocytosis [25,77–79]. Indeed, downstream EGFR signaling
pathways including the GTPase Harvey rat sarcoma viral oncogene homolog (HRas) have been
shown to be required for HCV entry, particularly for the formation of the CD81-CLDN1 co-receptor
complex that is essential for this process (reviewed in [80]). Thus, HCV entry can be efficiently
inhibited using antibodies, peptides or other molecules binding to SR-BI, CD81, CLDN1, EGFR and
TfR1 as well as small molecule inhibitors of EGFR, EphA2, GAK, NPC1L1 and HRas [25,77,78,81–96]
(Figure 2). Furthermore, host antiviral immune responses may also contribute to inhibiting HCV
entry by interfering with the viral entry process as demonstrated by the inhibition of the EGFR kinase
activity and, consequently, CD81-CLDN1 co-receptor formation via induction of IFN-α inducible
protein 6 (IFI6), an IFN-stimulated gene (ISG) [97].
Following internalization via clathrin-mediated endocytosis, the viral genome is released into the
cytoplasm after fusion of viral and endosomal membranes. In addition to some of the compounds
described above, HCV endocytosis and/or fusion can be efficiently perturbed using amphipathic
DNA polymers and small molecules including two anti-malaria drugs (chloroquine, ferroquine),
arbidol and sylimarin/silibinin [98–103] (Figure 2). Of note, in addition to its interference with HCV
entry, silymarin/silibinin-derived compounds and chloroquine have also been reported to interfere
with viral replication [100,104,105].
In addition to cell-free virus entry, HCV has been shown to also directly infect neighboring
hepatocytes via a process called cell-to-cell transmission [106–108]. In contrast to the cell-free
HCV entry described above, HCV cell-to-cell transmission is resistant to most of the neutralizing
antibodies described so far and is thus believed to play a major role in the maintenance of chronic
infection. Although the detailed molecular mechanisms remain to be uncovered, it has been
reported that the HCV envelope glycoproteins and apoE on the virus particle as well as CD81,
SR-BI, CLDN1, OCLN, EGFR, EphA2 and NPC1L1 on the host cell play an important role for
cell-to-cell transmission [19,24,25,77,92,106–108] (Figure 2). Of note, it has been described that HCV
can circumvent CD81 and SR-BI for this process [108,109]. However, the potential consequences for
antiviral therapy targeting entry factors remain unknown (also see Section 3 below). Notably, viral
variants that appear not to require SR-BI for their in vitro infectivity remain sensitive to SR-BI-specific
antibodies in vivo, as demonstrated using the human liver-chimeric uPA-SCID mouse model [20].
Host-targeting entry inhibitors (HTEIs) including antibodies directed against host entry factors
or co-factors as well as small molecule inhibitors have proven to efficiently prevent/delay HCV
infection in the human liver-chimeric uPA-SCID mouse model [18,24,25,99,110,111], and, thus,
may represent a valuable strategy to prevent liver graft infection following LT. Furthermore, they
may also contribute to treatment of chronic hepatitis C since an antibody targeting CLDN1 has
recently been shown to cure chronic HCV infection in human liver-chimeric uPA-SCID mice in the
absence of detectable toxicity [24]. Finally, their combination with other HTAs and/or DAAs can
result in a synergistic antiviral activity [21], which provides perspectives for novel combination
therapies for the cure of chronic hepatitis C (also see Section 3 below). Collectively, these data
highlight the potential of HTEIs not only for prevention of HCV infection, e.g., during LT, but
also for treatment of chronic hepatitis C. Of note, a phase 1/2 clinical trial evaluating erlotinib,
a clinically licensed EGFR inhibitor used in cancer therapy, has been initiated in chronic HCV patients
(https://clinicaltrials.gov/; Identifier: NCT01835938). Furthermore, silymarin/silibinin-derived
compounds have been evaluated in phase 2/3 clinical trials and (case) reports suggest their efficacy
in decreasing viral loads in chronic HCV patients and prevention of hepatitis C recurrence after
LT, although other studies reported viral rebounds [26,112–115]. Whether this potential effect is
(partially) due to silymarin/silibinin’s interference with viral entry remains to be defined. While the
efficacy of chloroquine for treatment of non-response HCV patients is currently being evaluated
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in a phase 4 clinical trial (https://clinicaltrials.gov/; Identifier: NCT02058173), no clinical trial of
ferroquine in hepatitis C patients has been registered so far.
2.2. Translation Inhibitors to Prevent Subsequent Viral Replication
Following viral endocytosis and fusion, HCV RNA is translated in an internal ribosome entry site
(IRES)-mediated manner. The highly conserved IRES is located in the 51-untranslated region (51-UTR)
of the viral genome [116,117]. HCV can thus directly recruit the translation initiation complex to
the viral RNA to trigger viral protein translation via a cap-independent mechanism. The HCV IRES
binding to the 40S ribosomal subunit is independent of canonical or non-canonical initiation factors.
Moreover, HCV translation initiation only requires eukaryotic initiation factors (eIF) eIF2, eIF3 and
eIF5 [118,119]. In contrast, optimal IRES activity is supported by the recruitment of several host
proteins named IRES transacting factors (ITAFs) (for a review, see [7]), which represent a novel
target for therapeutic intervention. Indeed, a synthetic peptide corresponding to the N-terminal 18
amino acids of the La antigen (efficiently blocks HCV translation by binding and sequestering other
ITAFs [120].
IRES-ribosome interaction has been shown to be mediated through the binding of the 40S
subunit to the stem loop III, domain e and f (SLIIIef), of the HCV IRES. A recent study demonstrated
that a small RNA mimicking the SLIIIef domain (SLRef) selectively inhibits HCV translation by
retaining the ability to interact with the 40S subunit. Interestingly, in line with previous studies,
it was shown that the anti-HCV activity of SLRef could be mainly due to interaction and sequestration
of the La antigen [121]. Ribosome-HCV IRES association can also be disturbed by prostaglandin
A1 (PGA1) which exhibits dose-dependent inhibitory effects on HCV translation [122]. Indeed, its
antiviral effect occurs through PGA1/eIF3-40S subunit/HCV IRES RNA complex formation which
inhibits HCV IRES-mediated translation. Furthermore, repetitive PGA1 treatment appears to be safe
in cell culture [122]. The in vivo efficacy of molecules interfering with HCV IRES-ribosome association
remains to be determined.
Furthermore, microRNA-122 (miR-122) plays an important role in HCV translation. MiR-122,
one of the most abundant liver-expressed miRNAs, binds to the HCV genome and enhances viral
translation and replication [123,124]. Sequestering miR-122 using miravirsen, a locked nucleic
acid-modified oligonucleotide complementary to the 51-end of miR-122, showed prolonged and
dose-dependent reduction in HCV viremia in patients without evidence of long-term safety
issues [28,29] (also see Section 2.4 below).
Recently, the receptor for activated C kinase 1 (RACK1), a component of the ribosomal 40S
subunit [125,126], was identified as an essential factor for HCV IRES-mediated translation [127].
Interestingly, RACK1 is not required for the classical cap-dependent translation and inhibition of
RACK1 expression in cell culture models did not reveal major toxicity [127]. Thus, the development
of RACK1 inhibitors may be an attractive perspective for future anti-HCV therapy.
2.3. Replication Inhibitors to Inhibit Viral Genome Amplification
Following translation and cleavage of the HCV polyprotein, the viral replicase complex,
composed of HCV non-structural (NS) proteins, NS3, NS4A, NS4B, NS5A and NS5B, is assembled.
HCV replication is a highly coordinated process involving host factors in addition to the replicase
complex. Several functional small interfering RNA (siRNA) and chemical screens have been
performed to uncover host factors involved in HCV replication and have provided useful insights
into this process [128–135].
HCV has been demonstrated to remodel intracellular membranes, including endoplasmic
reticulum (ER) membranes, for its replication and this process takes place at the so-called
“membranous web” [136]. Indeed, HCV NS proteins induce the formation of double-membrane
vesicles [136–139]. It has been suggested that this process may be linked to the activation of the
autophagy pathway [140], a cellular catabolic process where protein aggregates and damaged
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organelles are removed for recycling. Indeed, several studies suggested that HCV activates the
autophagic pathway to support its replication (reviewed in [141,142]). Moreover, HCV replication
has been reported to occur on autophagosomal membranes [140,143]. This may enable the virus
to conceal its RNA and evade double-stranded RNA-triggered host antiviral responses [140].
Chloroquine has been described as an inhibitor of autophagic protein degradation and, in addition
to inhibiting HCV entry by modulating endosomal acidification [98], chloroquine has been shown to
reduce HCV replication [105]. Host proteins have also been reported to contribute to the formation
of double-membrane vesicles (reviewed in [144]), e.g., cyclophilin A (CypA), which interacts with
NS5A, and proline-serine-threonine phosphatase interacting protein 2 (PSTPIP2), which interacts
with NS4B and NS5A [145,146]. The importance of CypA for the HCV life cycle has recently been
underscored in a humanized mouse model of HCV infection in which the Ppia gene had been
knocked out [147]. In addition to CypA, several other cyclophilins (Cyps) have been reported
to also contribute to HCV replication [128,148–150]. Cyclosporines are classical Cyp inhibitors;
however, their immunosuppressive properties preclude their use as antivirals. Within the past years,
several alternative Cyp inhibitors have been generated: cyclosporine A (CsA) derivatives without
immunosuppressive properties and new molecules structurally unrelated to CsA (reviewed in [151]).
Cyp inhibitors were the first class of HTAs against HCV reaching clinical development. Three
non-immunosuppressive Cyp inhibitors have so far demonstrated clinical efficacy in chronic hepatitis
C patients in IFN-based as well as IFN-free treatment regimens [32,151]. These Cyp inhibitors have
been shown to disrupt/prevent the formation of CypA-NS5A complexes and thereby inhibit HCV
replication [33,151–154]. In addition, the anti-HCV activity of CypA inhibitors may be increased
since they appear to restore the host innate immune responses to HCV [33].
NS5A is a central player within the membranous web as it interacts with a plethora of host
factors, thereby orchestrating viral replication. The lipid kinase phosphatidyl-inositol-4-kinase III
alpha (PI4KIIIα) is one of the major NS5A partners in this process [155]. Indeed, NS5A binds to and
activates PI4KIIIα and this, in turn, regulates the phosphorylation status of NS5A [156]. PI4KIIIα
activity leads to phosphatidyl-inositol-4-phosphate (PI4P) accumulation within the membranous
web and likely the subsequent recruitment of cellular lipid transporters leading to the modulation
of its lipid content (reviewed in [144]). In the absence of PI4KIIIα activity or through alteration
of its interaction with NS5A, changes in the ultrastructural morphology of the membranous HCV
replication complex were observed [132,155,156]. PI4KIIIβ has also been reported to contribute
to the replication of HCV genotype 1 but not genotype 2 [157,158]. PI4KIII inhibitors able to
reduce HCV replication in vitro have been developed, but their in vivo toxicity as well as the
lethal phenotype of transgenic mice exhibiting kinase-defective PI4KIIIα preclude their further
clinical development as antivirals [134,158–161]. As stated above, the host cell lipid metabolism
plays an important role in the HCV replication complex [162]. Particularly elements of cholesterol
and fatty acid synthesis and geranylgeranylation of host proteins have been shown to modulate
viral replication. Indeed, several genes involved in lipid metabolism have been reported to be
modulated during acute HCV infection of chimpanzees [163]. HCV replication can be disrupted
in vitro by treatment with inhibitors of 3-hydroxy-3-methylglutaryl CoA (HMGCoA) reductase or
with an inhibitor of protein geranylgeranyl transferase I [164,165]. Notably, not all HMGCoA
reductase inhibitors affect HCV replication, suggesting the existence of a different structure-activity
relationship between the anti-HMGCoA reductase activity and the antiviral activity [166]. Fluvastatin
is a statin that has been reported to increase the efficacy of IFN-based treatment in chronic
HCV-infected patients [30,31,167,168]. Recent in vitro studies have provided novel insights into
the mechanism of action of fluvastatin. The anti-HCV effect of fluvastatin has been suggested to
be due to the induction of microtubule bundling and a decrease of expression of the microtubule
binding partner doublecortin-like kinase 1 (DCLK1) [169]. Furthermore, fluvastatin and other
statins exhibiting an antiviral effect against HCV induce the expression of heme oxygenase-1 (HO-1),
which has been reported to reduce HCV replication [170–173]. HMGCoA reductase activity can
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also be inhibited using SKI-1/S1P inhibitors [174,175]. In addition to inhibiting HCV replication,
SKI-1/S1P inhibitors may also reduce the production of new virions [174]. Interestingly, it has
also been reported that antibody-mediated blocking of the LDLR leads to an increase in the
ratio of phosphatidylethanolamine to phosphatidylcholine in host cells and a decrease in HCV
replication [64], further strengthening the link between lipid metabolism and HCV replication.
Moreover, a functional chemical compound screen identified the estrogen receptor alpha (ESRα)
as an interaction partner of NS5B within lipid rafts on ER membranes [176]. Indeed, tamoxifen,
a partial ESR agonist and prototype selective estrogen-receptor modulator, as well as a decoy
peptide against ESRα-NS5B interaction inhibited HCV replication and ESRα-NS5B interaction
in the replicase complex [176]. ESRα may thus also represent a potential target for anti-HCV
therapy. Finally, it has been recently reported that HCV replication can also be inhibited by
cholesterol-25-hydroxylase (CH25H) whose expression is increased upon HCV infection [177–179].
CH25H synthesizes 25-hydroxycholesterol (25HC) which displays antiviral activities against different
enveloped viruses and may thus represent a broad-spectrum antiviral [163,180]. The anti-HCV
activity of CH25H appears to be mediated through 25HC-dependent and independent events
including the interaction with NS5A that prevents NS5A dimerization required for viral replication,
the inhibition of the formation of the membranous web, and the disruption of the function of the
transcription factors sterol regulatory element-binding proteins (SREBPs), thereby perturbing the host
lipid metabolism [177,179].
In addition to its role in HCV genome translation as described above, miR-122 is a
hepatocyte-specific host factor essential for HCV replication. Indeed, HCV cannot replicate in
cells lacking miR-122 or in which miR-122 has been sequestered [123,181–185]. The viral RNA
contains two adjacent miR-122 sites in its 51 UTR and miR-122 binding to the HCV genome promotes
viral replication [186,187]. MiR-122 thus represents an interesting target for antiviral therapy
(reviewed in [188]) and the miR-122 inhibitor miravirsen has proven its efficacy in reducing viral
loads in chronic hepatitis C patients in phase 1/2 clinical trials [28,29]. The antiviral activity of
miravirsen may be due to two complementary mechanisms: the hybridizing to mature miR-122
that blocks its interaction with HCV RNA, and the binding to the stem-loop structure of pri- and
pre-miR-122 that inhibits processing of miR-122 precursors [189].
Besides inhibiting host factors required for viral replication, HCV replication may also be
inhibited by modulating host factors that restrict HCV replication, e.g., the elongation factor Tu
GTP binding domain containing 2 (EFTUD2) and the human cytidine deaminase APOBEC3G
(hA3G) [190–192]. Interestingly, hA3G stabilizers exhibit antiviral activity against HCV as hA3G
binds to NS3, thereby inhibiting its helicase activity required for viral replication [190,193]. Given
their original mechanism of action, this class of HTAs may deserve further research to optimize
their activity.
Interestingly, compounds inhibiting histone deacetylase 6 (HDAC6) have also been reported to
inhibit HCV replication [194,195]. The mechanism of action appears to involve hyperacetylation of
α-tubulin [194]. Finally, a signal transducer and activator of transcription 3 (STAT3) inhibitor with
anti-HCV effect has recently been uncovered in a high-throughput screen [135]. Indeed, STAT3
has been reported to be activated by HCV core and NS5A and to act as a proviral factor for
HCV replication [196–198].
2.4. Assembly/Release Inhibitors to Prevent Generation and Release of New Virions
A remarkable hallmark of HCV is its association with VLDL/low density lipoprotein (LDL) to
form an infectious lipoviroparticle (LVP) [199]. Intracellular assembly and egress of LVP depend
on numerous factors involved in lipid metabolism (reviewed in [162,200]) and are closely linked
to the VLDL production machinery [201]. Among the main factors involved in this process are
lipid droplets (LDs), intracellular organelles that originate from triglyceride (TG) and cholesterol
ester (CE) accumulation between the two leaflets of the ER bilayer [202]. This microenvironment
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represents the “platform” for HCV particle assembly. Several host factors involved in TG biosynthesis
and LD biogenesis have been demonstrated to contribute to this process and thus represent targets
for HTAs (Figure 3). Indeed, HCV morphogenesis is triggered by the recruitment of the viral core
protein from the ER to LDs [203], a process mediated by the diacylglycerol acyltransferase-1 (DGAT-1)
(Figure 3). Interestingly, a DGAT-1 chemical inhibitor, currently in clinical trials for metabolic diseases
(reviewed in [204]), might serve as an antiviral against HCV infection [205]. Notably, since in
hepatocytes DGAT-2 has redundant functions in LD morphogenesis, this DGAT-1-specific inhibitor
did not impair LD homeostasis in vitro [205]. The safety of DGAT-1 inhibitor LCQ908 has already
been evaluated in HCV-infected patients (https://clinicaltrials.gov/; Identifier: NCT01387958),
but additional studies are needed to assess its antiviral efficacy in patients.
Core recruitment to LDs also depends on the composition and the fluidity of ER lipid
bilayers that is regulated by the cytosolic phospholipase A2, group 4A, (PLA2G4A) and upstream
mitogen-activated protein kinases-extracellular signal regulated kinases (MAPK/ERK). PLA2G4A
has been shown to contribute to HCV assembly since pyrrolidine-2 (Py-2), a chemical inhibitor
of PLA2G4A, induces aberrant HCV particle production [206]. Furthermore, selective inhibitors
of the MAPK/ERK pathway can block infectious HCV production [206,207]. However, opposite
studies demonstrated that inhibition of the Ras/Raf/MEK/ERK pathway enhances HCV
translation/replication, and disturbs IFN signaling [208–210]. The potential of MAPK inhibitors
as antivirals thus remains to be further investigated. The cytosolic phospholipase A2, group 4C,
(PLA2G4C) is another enzyme involved in LD homeostasis that can be targeted by HTAs to inhibit
assembly. Indeed, the “methyl arachidonyl fluorophosphonate” molecule (MAFP) significantly
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Figure  3.  Schematic  representation  of  HCV  assembly.  Virion  assembly  is  triggered  by  core 
recruitment on cytosolic  lipid droplets (cLDs) by the diacylglycerol acyltransferase‐1 (DGAT‐1). In 
turn, replication complexes are recruited  through core‐NS5A  interactions. Nucleocapsid  formation 
is mediated by viral budding into the ER lumen, at the site of VLDL production. The immature viral 




Figure 3. Schematic representation of HCV assembly. Virion assembly is triggered by core
recruitment on cytosolic lipid droplets (cLDs) by the diacylglycerol acyltransferase-1 (DGAT-1).
In turn, replicat on complexes are recruited through core-NS5A interacti s. Nucleocapsid formation
is mediated by viral budding into the ER lumen, at the site of VLDL production. The immature
viral particles fuse or attach to a luminal LD (LuLD) through apoE-E1E2 and apoE-NS5A interactions.
During VLDL synthesis, apolipoprotein B (apoB) is directly produced in the ER lumen and enriched
in lipids by the microsomal triglyceride transfer protein (MTP) to generate VLDL precursors. Viral
particles merge with these nascent VLDLs to generate mature lipoviroparticles (LVPs). LVPs enter the
VLDL maturation and secretion pathway to be released from hepatocytes. HCV assembly and egress
can be impaired by targeting different steps of these processes as highlighted in red.
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Directly targeting core trafficking in hepatocytes also represents an interesting antiviral strategy
given the numerous host factors involved in this process (Figure 3). These include AP2M1, the
µ subunit of the clathrin adaptor protein complex 2 (AP-2) that interacts with the core protein
through a process involving the adaptor-associated kinase 1 (AAK1) and the cyclin-associated
kinase (GAK) [79,96,212]. Approved anticancer kinase inhibitors, such as erlotinib or dasatinib
targeting GAK and sunitinib or PKC-412 targeting AAK1, can disrupt core-AP2M1 interaction
and, thus, HCV assembly [79,96,213]. However, it has to be pointed out that these compounds
were initially designed to target other kinases—some of which are involved in HCV entry
(see Section 2.1 above)—and thus lack selectivity for GAK and AAKI. The recently reported GAK
inhibitor isothiazolo[5,4-b]pyridine that displays limited off-target binding to other kinases efficiently
inhibits HCV entry and assembly, and may thus be further developed as a potential antiviral [96].
Other HTAs interfering with host cell lipid metabolism have been reported to display antiviral
activity against HCV. Indeed, resveratrol that increases the expression of PPARα, a nuclear
transcription factor that activates fatty acid oxidation and is decreased by the core protein [214,215],
impairs HCV assembly and secretion by enhancing consumption of fatty acids [216]. Moreover,
recent screens identified pterostilbene, a methylated form of resveratrol, toremifene, an estrogen
receptor modulator similar to tamoxifen, and quinidine, an antiarrhythmic drug, as potential
antivirals against HCV [11,12]. Naringenin was also shown to block production of infectious HCV
particles through the activation of PPARα [36]. Interestingly, HCV can also repress PPARα activity
and lipid accumulation by inducing up-regulation of miR-27b and bezafibrate, a PPARα agonist,
which reverses miR-27b-induced lipid accumulation [217]. This indicates the potential of additional
strategies to design novel HTAs against HCV.
Besides core, NS5A is another major player within the HCV replication cycle that connects
replication and assembly. NS5A-core interaction on LDs is a crucial step for viral assembly [203,218–220].
Assembly competence of NS5A is mediated by the Caseine Kinase (CK)-mediated phosphorylation
of multiple serine and threonine residues [221,222]. Indeed, the specific CKII inhibitor,
2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT), was shown to dramatically
disrupt virion biogenesis [221] (Figure 3). However, HCV genotype 1a virus production did not
appear to be affected by DMAT [223]. Thus, genotype-specific differences might have to be taken into
account for potential future clinical application of such inhibitors. To date, one chemical inhibitor of
CKII, CX-4945, has entered clinical trials for its antitumor activity, but the potential antiviral effect
against HCV remains to be determined [224].
HCV particle assembly and egress appear to share several host factors with VLDL assembly and
secretion pathways [201,225] (Figure 3). The early step of VLDL synthesis consists of lipidation of the
newly synthetized apolipoprotein B (apoB) across the ER membrane by the microsomal triglyceride
transfer protein (MTP). In the second step, the VLDL precursors are enriched in lipids via fusion
with resident apoE containing LDs (for a review, see [226]). Accumulating evidence demonstrates
the crucial role of apoE in HCV assembly [62,63,227–231], while the role of apoB and MTP still
remains unclear and controversial [62,63,201,225,232]. Nevertheless, a recent study demonstrated
the ability of amiodarone, a cationic amphipathic drug that inhibits MTP activity, to down-regulate
HCV assembly and release in cell culture [233] (Figure 3). Several other MTP inhibitors are in clinical
trials for the treatment of hyperlipidemia (reviewed in [234]). However, whether amiodarone and
other MTP inhibitors display an antiviral effect against HCV in vivo remains to be determined.
The VLDL secretory pathway is also hijacked to facilitate HCV egress from infected
hepatocytes [201,225] (Figure 3). VLDL secretion is regulated by the hepatocyte nuclear factor 4α
(HNF4α), the most abundant transcription factor in the liver. Interestingly, HNF4α also regulates
expression of phospholipase A2 GXIIB (PLA2GXIIB), a crucial host factor for HCV production [235].
HNF4α down-regulation by bezafibrate dramatically reduced HCV secretion [235]. In line with
this study, a meta-analysis showed that bezafibrate is associated with a reduction of viral load in
chronically HCV-infected patients [168]. Moreover, in association with IFN and ribavirin, bezafibrate
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has been reported to reduce serum HCV RNA titers and to improve liver dysfunction [37]. Cyps
have also been reported to contribute to HCV virion secretion in addition to their role in viral
replication [150]. The Cyp inhibitor NIM811 alters lipid trafficking and decreases apoB secretion
through the VLDL pathway, thereby blocking HCV production [236]. The combination of NIM811
with PEG-IFNα showed significant antiviral activity compared to IFN alone in chronically infected
HCV patients [34]. This synergistic effect may be due to the inhibition of both HCV replication and
assembly by NIM811.
To counteract HCV proliferation, several studies reported a novel antiviral strategy that uses
the human heat shock cognate protein 70 (Hsc70) as an antiviral target [237–240]. Hsc70 was
identified as a part of the viral particle that modulates virion capsid assembly and LD-dependent
virus release [241]. IMB-DM122 [237] and N-substituted benzyl matrinic acid [239] inhibit Hsc70
expression through destabilization of Hsc70 mRNA. Treatment of HCV-infected hepatocytes with
these components reduced the incorporation of Hsc70 into viral nucleocapsids, and therefore
disrupted HCV production. Moreover, both compounds demonstrated good oral pharmacokinetic
profiles and high safety in vivo, making these molecules promising candidates for clinical
trials [237,239]. Recently, it has been reported that (+)-lycoricidine exhibits anti-HCV activity through
its inhibitory effect on the expression of Hsc70 [238]. However, the significant cytotoxicity of this
compound precluded further development and new phenanthridines with reduced toxicity have
been designed [240]. Their potential as antivirals remains to be determined.
Finally, a promising strategy developed to inhibit virion assembly is to interfere with
glucosidases that ensure N-glycosylation and folding of HCV envelope glycoproteins E1 and E2 [242]
(Figure 3). It was shown that celgosivir, an α-glucosidase I inhibitor, leads to reduced viral production
and infectivity in vitro. Moreover, celgosivir administration in combination with PEG-IFN α and
ribavirin displayed a clinical benefit in genotype 1 chronically infected patients (reviewed in [35]).
Long-term studies are needed to confirm its safety in humans.
3. HTAs to Prevent HCV Resistance
Given that they target a highly variable virus, the main limitation of DAAs is viral resistance.
Viral resistance may be prevented using different strategies including (i) targeting conserved viral
sequences less prone to mutation; (ii) using a combination of drugs exhibiting distinct targets and
mechanisms of action; and (iii) increasing host antiviral responses. In contrast to the first DAAs,
the emergence of viral resistance with recently approved DAAs, such as sofosbuvir, is less frequent
but has nevertheless been described [2,243–245]. Given the generally lower barrier to resistance
of DAAs as compared to HTAs, the emergence of treatment-resistant viral variants during DAA
therapy remains a challenge. By acting through a complementary mechanism of action and by
exhibiting a generally higher barrier to resistance, HTAs can be associated with DAAs to prevent
viral resistance. Indeed, given their complementary mechanism of action, HTAs and DAAs can
act in a synergistic manner to reduce viral loads [13,21,103] (Figure 4). Interestingly, various HTAs
may also be combined to synergistically inhibit HCV infection, as demonstrated for combinations
of a HTEI and host-targeting replication inhibitor, i.e., a Cyp inhibitor [21]. Furthermore, HTEIs
have been demonstrated to prolong viral suppression by DAAs and to prevent viral dissemination
of DAA-resistant strains in vitro [21,246,247]. Indeed, although treatment of HCV-infected cells
with DAAs rapidly results in a dramatic reduction of viral load in vitro, viral rebound is usually
observed following withdrawal of the drug. However, the addition of an HTEI to the cell culture at
the time of DAA withdrawal allows the further decrease of the viral load, indicating that HTEIs
limit viral rebound from DAA therapy [21,246]. Furthermore, as many HTEIs inhibit cell-to-cell
transmission that has been shown to represent the major route of transmission of wild type and
DAA-resistant viruses, HTEIs have been demonstrated to limit dissemination of DAA-resistant
strains and consequently prevent antiviral resistance [247]. In line with these in vitro data, the
Cyp inhibitor alisporivir, currently in phase 2/3 clinical trials, has been shown to efficiently reduce
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viral loads in chronic hepatitis C patients in combination with ribavirin [32] and future clinical
trials evaluating its antiviral effect in combination with DAAs will provide further insights into the
potential of this HTA.
Thus far, no viral resistance to HTAs was observed in preclinical or clinical studies [24,28,248].
However, some resistant viral variants could be selected by viral passaging in vitro [75,103]. This
has been first evidenced and most extensively studied with Cyp inhibitors [249–252]. Of note,
it was difficult to generate variants exhibiting Cyp inhibitor resistance and the time required to
select resistance against these HTAs was significantly longer as compared to DAAs; furthermore,
the resistance level was lower [249,250]. These data suggested that these viral variants were less
dependent on CypA-dependent isomerization of NS5A for their replication [250]. Moreover, while
prolonged administration of miravirsen (a miR-122 inhibitor) did not result in the emergence of
viral variants exhibiting mutations within the miR-122 binding regions in preclinical and clinical
trials [28,248], viral variants exhibiting a single nucleotide change in the 51UTR between the miR-122
binding sites and requiring less miR-122 for their replication could be identified in vitro [253].
Whether the emergence of such variants could be avoided by combining miravirsen with other HTAs
and/or DAAs with anti-HCV activity remains to be determined. Collectively, these studies indicate
that HCV may become less dependent on defined host factors under selection pressure in vitro. While
most mutants were still dependent on Cyp and/or miR-122, specific mutations in NS5A eliminated
the dependence of HCV RNA replication on the expression of host CypA [152]. Notably, a recent
study reported that HCV is able to change its host factor dependency under selection pressure.
Indeed, in CLDN1 knock-out cells, a CLDN1-dependent strain was able to evolve to use CLDN6
or CLDN9 as a receptor [75]. Whether this may occur in vivo where CLDN1 is expressed at much
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life cycle. Given their complementary mechanism of action, HTAs and DAAs can act in a synergistic Figure 4. Synergy between HTAs and DAAs to inhibit HCV infection at different steps of the viral
life cycle. Given their complementary mechanism of action, HTAs and DAAs can act in a synergistic
manner to reduce viral loads and to prevent viral resistance. Different classes of HTAs and DAAs that
have been evaluated in combination are highlighted in red.
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4. Conclusions and Perspectives
During the last decade, the development of new DAAs considerably improved anti-HCV
therapy, displaying high cure rates in treated patients. However, treatment failure and resistance
in a subset of patients remain a challenge. Alternative approaches targeting host factors involved in
HCV pathogenesis offer new treatment opportunities. Due to low genetic variability of host factors,
HTAs exhibit a high genetic barrier to resistance and display a pan-genotypic antiviral activity.
Several HTAs are currently in development in preclinical or clinical trials (Table 1).
Proof-of-concept studies on alisporivir and miravirsen have already shown very high cure rates in
phase 2 and 3 clinical trials when used in monotherapy. Preclinical studies have also demonstrated the
potential synergistic activity of HTA/DAA combinations to cure HCV infection (Figure 4). Synergy
between DAAs and HTAs offers a prospective option for combination therapies for treatment failure
to licensed therapies. Furthermore, entry inhibitors, such as anti-receptor antibodies, could offer
prevention for HCV graft infection during LT. Indeed, it has been shown that such inhibitors impair
cell infection of highly variable quasispecies isolated from individual patients as well as escape
variants resistant to host neutralizing antibodies [25,77,78,81–96]. However, their clinical efficacy
remains to be demonstrated. To conclude, HTAs may widen the therapeutic arsenal against chronic
HCV infection and simplify HCV therapy.
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